Department of Medical Technology, School of Allied Health Sciences, University of Phayao, Phayao, Phayao Province, Thailand.
Department of Medical Technology, Maesot Hospital, Tak, Tak Province, Thailand.
Hemoglobin. 2020 Nov;44(6):385-390. doi: 10.1080/03630269.2020.1848860. Epub 2020 Nov 22.
Hb E [β26(B8)Glu→Lys, AG>AG, : c.79G>A] is an inherited thalassemic β-globin variant that favors the Hb E-β-thalassemia (β-thal) syndrome when interacting with the β-thal gene. However, hemoglobin (Hb) variants carrying Hb E in combination with another variant on the same β gene are rare. We recently studied a 29-year-old pregnant woman, initially diagnosed as a β-thal carrier. Hemoglobin and DNA analysis were performed by high performance liquid chromatography (HPLC) and DNA sequencing. Hematological data revealed no anemia or altered red blood cell (RBC) parameters. Hemoglobin HPLC showed Hb A and Hb A but no Hb E or abnormal Hb peaks, with a markedly elevated Hb A level (6.4%) reaching the accepted range (4.0-10.0%) for β-thal trait. DNA analysis identified a AG>AG transition at codon 26 of the β-globin gene that is responsible for Hb E, and an AA>AA mutation at codon 65 in on the β-globin chain resulting in a lysine to asparagine substitution. These two mutations led to the formation of a novel variant, namely Hb E-Myanmar, β26(B8)Glu→Lys and β65(E9)Lys→Asn, : c.[79G>A;198G>C]. Moreover, a heterozygous α-thalassemia-2 (α-thal-2) [-α (rightward)] deletion was also observed. Hb E-Myanmar is a doubly substituted β-globin variant, which has not been previously described. This variant did not have any clinical or hematological abnormalities, and the genetic mechanism resulting in this variant is discussed. The new simultaneous allele-specific polymerase chain reaction (ASPCR) was developed for rapid detection of these two mutations within the same β-globin chain.
Hb E [β26(B8)Glu→Lys, AG>AG, : c.79G>A] 是一种遗传性的β珠蛋白变体,当与β珠蛋白基因相互作用时,有利于形成 Hb E-β-地中海贫血(β-地贫)综合征。然而,在同一β基因上携带 Hb E 与另一种变体的血红蛋白变体非常罕见。我们最近研究了一位 29 岁的孕妇,最初被诊断为β-地贫携带者。通过高效液相色谱(HPLC)和 DNA 测序进行血红蛋白和 DNA 分析。血液学数据显示无贫血或改变的红细胞(RBC)参数。血红蛋白 HPLC 显示 Hb A 和 Hb A,但没有 Hb E 或异常 Hb 峰,Hb A 水平显著升高(6.4%)达到β-地贫特征的可接受范围(4.0-10.0%)。DNA 分析确定β-珠蛋白基因 26 密码子处的 AG>AG 转换负责 Hb E,β-珠蛋白链 65 密码子处的 AA>AA 突变导致赖氨酸取代为天冬酰胺。这两个突变导致形成一种新的变体,即 Hb E-缅甸,β26(B8)Glu→Lys 和β65(E9)Lys→Asn,:c.[79G>A;198G>C]。此外,还观察到杂合的α-地中海贫血-2(α-地贫-2)[-α(右移)]缺失。Hb E-缅甸是一种双取代的β-珠蛋白变体,以前没有描述过。该变体没有任何临床或血液学异常,并讨论了导致该变体的遗传机制。开发了新的同时等位基因特异性聚合酶链反应(ASPCR),用于快速检测同一β-珠蛋白链中的这两种突变。